BioSpace News Archive

Business

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and recent business highlights for the first quarter of 2024.

May 9, 2024
·
11 min read
Business

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics, Inc. reported first quarter 2024 financial results and provided operational highlights.

May 9, 2024
·
7 min read
Biotech Beach

Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meeting

KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures and an exclusive license of KT430 to Astellas Pharmaceuticals for the treatment of X-linked myotubular myopathy.

May 9, 2024
·
6 min read
Genetown

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals announced that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher to an undisclosed purchaser for $105 million and that it has drawn an additional tranche of $20 million under its existing loan facility with Hercules Capital, Inc.

May 9, 2024
·
5 min read
Business

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

May 9, 2024
·
9 min read
Drug Development

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

TScan Therapeutics, Inc. announced that the first patient has been dosed in the Company’s Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors.

May 9, 2024
·
7 min read
Theravance Biopharma to Participate in an Upcoming May 2024 Investor Conference

Theravance Biopharma, Inc. will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT and will be hosting in-person meetings with the investment community at the conference.

May 9, 2024
·
1 min read
Business

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Limited, a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, reported its first quarter 2024 financial results, and recent business highlights.

May 9, 2024
·
10 min read
Business

ICON releases its ICON Cares 2023 Report

ICON plc, a world-leading healthcare intelligence and clinical research organisation, releases its ICON Cares 2023 Report.

May 9, 2024
·
5 min read
Business

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance

Mallinckrodt plc, a global specialty pharmaceutical company, reported its financial results for the first quarter ended March 29, 2024.

May 9, 2024
·
26 min read